Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress View Full Press Release Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)